Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
CYM-5541
Cat. No.:
OB0225LY-0083
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
CYM-5541 is a novel drug candidate that works by affecting the balance of neurotransmitters.
Synonym:
CYM 5541; ML249; 945128-26-7; CYM 5541; N, N-Dicyclohexyl-5-cyclopropyl-1,2-oxazole-3-carboxamide; N, N-Dicyclohexyl-5-cyclopropyl-3-isoxazolecarboxamide; N, N-Dicyclohexyl-5-cyclopropylisoxazole-3-carboxamide
CAS No.:
945128-26-7
Compound CID:
17253208
Formula:
C19H28N2O2
Formula Weight:
316.44
Specification
Relative Density:
1.14 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
CYM-5541 can be used to assess effectiveness and safety in mental health problems such as depression and anxiety.
Library Information
Targets:
S1P receptor; LPL receptor
Pathways:
GPCR/G protein
Plate Number:
AOCL-2
Plate Location:
a6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 158.01 mM
